However, studies assessing blood apoA2-ATQ/AT levels as a screening biomarker for early-stage PC, specifically stages 0 and I, while considering imaging findings from CT, MRI, and EUS, are currently lacking. Here, APOA2 is linked to pachyonychia congenita.